Management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics; reduction of fever.

Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties

-Distribution: Vd:Pediatric patients 6 months to <2 years: 0.31 L/kg.Pediatric patients 2 to 16 years: 0.23 L/kg.-Protein binding: >99%; Premature infants: ~95% (Aranda 1997).Bioavailability: 80%.-Half-life elimination: Infants 3 months to <6 months: 1.3 hours.Infants ?6 months to Children <2 years: 1.8 hours.Children ?2 years to Adolescents ?16 years: ~1.5 hours.Adults: 2.22 to 2.44 hours.

1.Patients allergic to ibuprofen. 2.Patients with active peptic ulcers, bleeding, or perforation; those with a history of NSAID-related gastrointestinal bleeding or perforation; those with a history of recurrent peptic ulcers or bleeding. 3.Patients with severe bleeding tendencies. 4.Severe hepatic failure. 5.Severe renal failure. 6.Patients who have experienced asthma, urticaria, or other allergic reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs. There have been reports of severe (rarely fatal) anaphylactic-like reactions in such patients. 7.This drug is contraindicated within 14 days after coronary artery bypass graft (CABG) surgery.

Teratogenic effects - Before 30 weeks of gestation: Category C; From 30 weeks of gestation onwards: Category D.

It is unknown whether ibuprofen is excreted into breast milk. Because many medications are excreted into breast milk, and because infants can potentially experience serious adverse reactions from ibuprofen, decisions regarding whether to discontinue breastfeeding or discontinue the medication should be made considering the importance of the medication to the mother.

?? The most common adverse reactions in clinical studies were nausea, bloating, vomiting, and headache (>5%).?? The most common adverse reactions in children are infusion site pain, vomiting, nausea, anemia, and headache (?2%).

-Analgesia: As adjunctive therapy to opioid analgesics, administer ibuprofen intravenously 400 to 800 mg every 6 hours, with an infusion time ? 30 minutes. -Fever reduction: Administer 400 mg intravenously, followed by 400 mg every 4 to 6 hours, or 100-200 mg every 4 hours as needed, with an infusion time ? 30 minutes. (The maximum daily dose for adults is not recommended to exceed 2400 mg.)

in children aged 6 months to 17 years: administer 10 mg/kg intravenously every 4 to 6 hours, with a maximum single dose of 400 mg, over an infusion period of not less than 10 minutes. The maximum daily dose is 40 mg/kg or 2400 mg, whichever is lower.

CrCl ?60 mL/minute: No dosage adjustment necessary CrCl >30 to <60 mL/minute: No dosage adjustment necessary CrCl ? 30 mL/minute: Avoid use due to increased risk of acute kidney injury

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution to avoid adverse effects and discontinue if hepatic function worsens.

stored below 30°C